# PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

> **NCT00544674** · PHASE2 · TERMINATED · sponsor: **Proacta, Incorporated** · enrollment: 5 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** PR104
- **OTHER:** F-18-fluoromisonidazole

## Key facts

- **NCT ID:** NCT00544674
- **Lead sponsor:** Proacta, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2009-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Terminated early due to discovery of new mechanism of activation.
- **Last updated:** 2012-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544674, "PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00544674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*